Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

BioMarin Pharmaceutical Inc. - Common Stock (NQ: BMRN )

64.19 +1.32 (+2.09%)
Streaming Delayed Price Updated: 4:00 PM EST, Feb 5, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 1,088,657
Open 63.00
Bid (Size) 63.00 (3)
Ask (Size) 65.00 (1)
Prev. Close 62.87
Today's Range 62.98 - 64.53
52wk Range 60.63 - 94.85
Shares Outstanding 183,352,255
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
For those who appreciate growth without the sticker shock, NASDAQ:BMRN is worth considering.
NASDAQ:BMRN is scoring great on several growth aspects while it also shows decent health and profitability. At the same time it remains remains attractively priced. 
Via Chartmill
NASDAQ:BMRN is an undervalued gem with solid fundamentals.
Take a closer look at BIOMARIN PHARMACEUTICAL INC , a remarkable value stock. NASDAQ:BMRN excels in fundamentals and maintains a very reasonable valuation. 
Via Chartmill

Performance

YTD
-3.47%
-3.47%
1 Month
-4.30%
-4.30%
3 Month
-2.81%
-2.81%
6 Month
-26.11%
-26.11%
1 Year
-26.83%
-26.83%

More News

Read More
Moderna, GameStop And Snap Are Among Top Large-Cap Losers Last Week (Jan 13-Jan 17): Are The Others In Your Portfolio?
Via Benzinga
NASDAQ:BMRN is showing decent growth, but is still valued reasonably.
Via Chartmill
Alger Launches Russell Innovation ETF To Capitalize On Emerging Innovators
Via Benzinga
Topics ETFs
NASDAQ:BMRN, a growth stock which is not overvalued.
Via Chartmill
The Latest Analyst Ratings For Biomarin Pharmaceutical
Via Benzinga
The Analyst Landscape: 29 Takes On Biomarin Pharmaceutical
Via Benzinga
10 Magnificent Stocks That Can Make You Richer in 2025
Via The Motley Fool
NASDAQ:BMRN stands out as a stock that provides good value for the fundamentals it showcases.
Via Chartmill
For those who appreciate growth without the sticker shock, NASDAQ:BMRN is worth considering.
Via Chartmill
When you look at NASDAQ:BMRN, it's hard to ignore the strong fundamentals, especially considering its likely undervaluation.
Via Chartmill
Can BioMarin Stock Live Up to Wall Street’s High Expectations?
Via MarketBeat
Peering Into Biomarin Pharmaceutical's Recent Short Interest
Via Benzinga
In-Depth Examination Of 29 Analyst Recommendations For Biomarin Pharmaceutical
Via Benzinga
A Look Ahead: Biomarin Pharmaceutical's Earnings Forecast
Via Benzinga
NASDAQ:BMRN stands out as a growth opportunity that won't break the bank.
Via Chartmill
CAMP4 Analyst Highlights Rare Disease Platform Potential
Via Benzinga
Topics Initial Public Offering
Exposures Securities Market
BioMarin's Pipeline Faces Skepticism As Analyst Questions Future Growth
Via Benzinga
Monopar Announces Agreement with Alexion, AstraZeneca Rare Disease For Late-Stage Wilson Disease Drug Candidate
From Monopar Therapeutics Inc.
Via GlobeNewswire
Investors seeking growth at a reasonable cost should explore NASDAQ:BMRN.
Via Chartmill
How Is The Market Feeling About Biomarin Pharmaceutical?
Via Benzinga
Analyst Expectations For Biomarin Pharmaceutical's Future
Via Benzinga
NASDAQ:BMRN appears to be flying under the radar despite its strong fundamentals.
Via Chartmill
Biden Administration Unveils Plan To Provide Generic Drugs for $2 to Medicare Recipients
Via Benzinga
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.